A Phase III clinical trial to assess if a potential vaccine is effective at preventing symptomatic COVID-19 is now open for enrollment by The University of Texas Health Science Center at Houston (UTHealth) in collaboration withMemorial Hermann-Texas Medical Center.

的study vaccine, AstraZeneca’s AZD1222, has been shown inearly-stage human trials产生阳性免疫反应。该审判旨在招募全国30,000名个人。休斯顿研究站点是纪念赫尔beplay苹果手机能用吗曼 - 德克萨斯医学中心的UTHEADY临床研究部门。

“The global infectious disease research community has united to launch numerous research studies as we search for treatment and prevention strategies for this illness. The development of a vaccine for COVID-19 is a critical step to help us return to normal,” saidRoberto C. Arduino, MD, the study’s lead investigator and professor of infectious disease withMcGovern Medical School在Uthealth。

Participants must be 18 years or older, healthy or have medically stable chronic diseases, have no known history of SARS-CoV-2 infection, and be at increased risk of infection. This includes, for example, people with stable underlying medical conditions, those with a high risk of exposure at their work, those over age 65, residents of elder care facilities, or individuals from racial and ethnic groups that have been impacted in greater numbers by the pandemic, such as African Americans, Latinx, and Native Americans.

Trial participants will be administered two doses of either the experimental vaccine or placebo (sterile salt water) four weeks apart. Preliminary数据已经提出，单剂量可以激发自适应免疫系统的两种主要机制 - 体液和细胞免疫反应。

Humoral immunity is also known as antibody-mediated immunity, which are antibodies primed to attack the SARS-CoV-2, the virus that causes COVID-19, if the person is in contact with the virus after the vaccination. Cellular immunity relies on T lymphocytes (white blood cells) to attack cells infected with SARS-CoV-2 virus. T lymphocytes, often called T cells, are responsible for conferring long-term immunological memory. Adaptive immunity is acquired through either infection or a vaccination. The early research also revealed that after the second dose of the vaccine, the body’s antibody response was heightened.

参与者将以2：1的比率随机分配，大约有20,000名参与者接受两剂AZD1222疫苗，10,000剂接受两剂安慰剂。该试验是双盲的，这意味着患者和研究人员都不知道将哪些研究组参与者放入。beplay苹果手机能用吗

的vaccine was developed by the University of Oxford and is composed of a weakened and nonreplicating version of the chimpanzee adenovirus that causes the common cold, which contains the genetic material encoding for the spike protein of the SARS-CoV-2 virus. This surface protein gives coronavirus its crownlike appearance and allows it to attach to and enter cells. The investigational vaccine is designed to promote the development of antibodies against the spike protein and prevent it from entering cells.

“This vaccine study is pivotal toward controlling the COVID-19 pandemic and it’s important that we reach out to the members of our community who have been especially impacted by this illness,” said Jonatan Gioia, MD, a research associate at McGovern Medical School at UTHealth and a project manager for the trial. Other co-investigators from McGovern Medical School include Carmel B. Dyer, MD, and Jessica Lee, MD, MS.

有关此审判的更多信息ClinicalTrials.gov, or emailCOVID19vaccinestudy@uth.tmc.edu.

To enroll in this trial visithttps://www.coronaviruspreventionnetwork.org/clinical-study-volunteer/(Site code:哈特).

的National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response, are providing funding support for the trial.

媒体咨询:713-500-3030